Compare Bank of America Corp (BAC) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of America Corp vs Cytokinetics Inc — how do they compare? Bank of America Corp trades at $64.02 (market cap $446.56B), while Cytokinetics Inc trades at $76.67 (market cap $10.78B). The key difference: Bank of America Corp is far larger — about 41.4× Cytokinetics Inc's market cap, and Bank of America Corp pays a 2% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| BAC | CYTK | |
|---|---|---|
Market Cap | $446.56B | $10.78B |
Volume | 55,637,172 | — |
Sector | Financials | Technology |
52-Week High | $64.00 | $87.26 |
52-Week Low | $46.72 | $34.31 |
Dividend Yield | 2% | — |
Enterprise Value | — | $10.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of America (BAC) trades at $64.00, up 1.31% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong fundamentals, including a P/E of 14.75 and net income margin of 28.21%, supported by revenue growth to $113.10 billion in 2025. Recent news highlights partnerships, hiring initiatives, and positive analyst coverage, with a consensus price target of $67.36.
Outlook remains positive with potential upside from capital returns and earnings growth, though risks include macroeconomic sensitivity and high RSI levels. Analyst consensus is strongly bullish with 64.82% buy ratings, indicating confidence in BAC's deposit franchise and operational strength amid evolving rate cycles.
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
